Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Ivabradine — a selective and specific If inhibitor: efficacy and safety in stable angina

K. Fox*

Royal Brompton Hospital, London, U.K.

* Kim Fox, Royal Brompton Hospital, Sydney Street, London, U.K.

Abstract

Aims To assess the antianginal and anti-ischaemic efficacy and safety of ivabradine in patients with stable angina.

Methods and results A total of 360 patients with stable angina were randomly assigned, in a double-blind fashion, to receive placebo or ivabradine 2.5 mg twice daily, 5 mg twice daily or 10 mg twice daily for 2 weeks. Patients voluntarily continued treatment (ivabradine 10 mg twice daily) in a 2- to 3-month, open-label extension period; this was followed by a randomized withdrawal period in which patients received ivabradine 10 mg twice daily or placebo for 1 week. Ivabradine was well tolerated, and no rebound phenomena were observed on treatment withdrawal. Dose-dependent significant reductions in heart rate were achieved at all dose levels (). Ivabradine 5 and 10 mg twice daily significantly increased time to 1-mm ST-segment depression () and time to limiting angina on exercise tolerance testing. Patients continuing on ivabradine during the withdrawal period maintained the improvements in exercise tolerance test criteria, whereas those who received placebo showed significant deterioration.

Conclusion Ivabradine (Procoralan®, Servier, Neuilly-sur-Seine, France) — a selective and specific inhibitor of the If (cardiac pacemaker, or ‘funny’) current — is a well-tolerated heart rate lowering agent with antianginal and anti-ischaemic efficacy in patients with stable angina. Results from the present study suggest that ivabradine could be a valuable alternative to current angina therapies.

Key Words: Exercise tolerance test • Heart rate • Ischaemia • Ivabradine • Stable angina • ST-segment depression

References

  1. Staniforth AP. Contemporary management of chronic stable angina. Drugs Aging. 2001;18:109–121[CrossRef][Web of Science][Medline]
  2. Heidenreich PA, McDonald KM, Hastie T, et al. An evaluation of beta-blockers, calcium antagonists, nitrates and alternative therapies for stable angina. Evidence Report/technology Assessment Number 10. AHRQ Publication No 00-E003. November 1999;:
  3. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature. 1986;324:470–473[CrossRef][Medline]
  4. DiFrancesco D. The contribution of the ‘pacemaker’ current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol. 1991;434:23–40[Abstract/Free Full Text]
  5. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993;73:197–227[Free Full Text]
  6. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051–1057[Web of Science][Medline]
  7. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37–42[Web of Science][Medline]
  8. Gardiner SM, Kemp PA, March JE, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257 [GenBank] , in conscious rats. Br J Pharmacol. 1995;115:579–586[Web of Science][Medline]
  9. Simon L, Ghaleh B, Puybasset L, Giudicelli J-F, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–666[Abstract/Free Full Text]
  10. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64:192–203[CrossRef][Web of Science][Medline]
  11. Ivabradine Investigators GroupBorer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–823[Abstract/Free Full Text]
  12. Fujiura Y, Adachi H, Tsuruta M, Jacobs DR Jr, Hirai Y, Imaizumi T. Heart rate and mortality in a Japanese general population: an 18-year follow-up study. J Clin Epidemiol. 2001;54:495–500[CrossRef][Web of Science][Medline]
  13. Kristal-Boneh E, Silber H, Harari G, Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J. 2000;21:116–124[Abstract/Free Full Text]
  14. Palatini P, Julius S. Relevance of heart rate as a risk factor in hypertension. Curr Hypertens Rep. 1999;1:219–224[Medline]
  15. Seccareccia F, Pannozzo F, Dima F, et al. for the Malattie Cardiovascolari Aterosclerotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health. 2001;91:1258–1263[Abstract/Free Full Text]
  16. Bel A, Perrault LP, Faris B, Mouas C, Vilaine J-P, Menasche P. Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations. Ann Thorac Surg. 1998;66:148–152[Abstract/Free Full Text]
  17. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987;59:26F–32F[CrossRef][Medline]
  18. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol. 1988;61:1219–1222[CrossRef][Web of Science][Medline]
  19. Kaneko A, Tachibana M. A voltage-clamp analysis of membrane currents in solitary bipolar cells dissociated from Carassius aureus. J Physiol. 1985;358:131–152[Abstract/Free Full Text]
  20. Demontis GC, Longoni B, Barcaro U, Cervetto L. Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol. 1999;515:813–828[Abstract/Free Full Text]
  21. Satoh TO, Yamada M. A bradycardiac agent ZD7288 blocks the hyperpolarization-activated current (I(h)) in retinal rod photoreceptors. Neuropharmacology. 2000;39:1284–1291[CrossRef][Web of Science][Medline]
  22. Fihn SD, Williams SV, Daley J, Gibbons RJ. American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine. Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med. 2001;135:616–632[Abstract/Free Full Text]
  23. Garratt KN. Stable angina pectoris. Curr Treat Options Cardiovasc Med. 2000;2:161–172
  24. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of patients with Chronic Stable Angina). Circulation. 1999;99:2829–2848[Free Full Text]
  25. Eur Heart J. 1997;18:394–413[Free Full Text]
  26. Bucher HC, Hengstler P, Schindler D, et al. Percutaneous transluminal angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ. 2000;321:73–77[Abstract/Free Full Text]
  27. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F–49F[CrossRef][Medline]
  28. Lechat P. Beta-blocker treatment in heart failure. Role of heart rate reduction. Basic Res Cardiol. 1998;93(suppl 1):148–155
  29. Berdeaux A, Drieu La Rochelle C, Richard V, Giudicelli JF. Opposed responses of large and small coronary arteries to propranolol during exercise in dogs. Am J Physiol. 1991;261:H265–H270
  30. Bortone AS, Hess OM, Gaglione A, et al. Effect of propranolol on coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. Circulation. 1990;81:1225–1235[Abstract/Free Full Text]
  31. Pepine CJ, Abrams J, Marks RG, Morris JJ, Scheidt SS, Handberg E. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol. 1994;74:226–231[CrossRef][Web of Science][Medline]
  32. Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf. 1993;4:272–279
  33. Boskabady MH, Snashall PD. Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta-blockade in asthma. Respirology. 2000;5:111–118[CrossRef][Medline]
  34. Tattersfield AE. Respiratory functions in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther. 1991;4(suppl 6):1229–1232
  35. Ramahi TM. Beta blocker therapy for chronic heart failure. Am Fam Physician. 2000;62:2267–2274[Web of Science][Medline]
  36. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J. 1988;116:1729–1734[CrossRef][Web of Science][Medline]
  37. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–1157
  38. Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ. 1989;298:1147–1152
  39. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind crossover study in hypertensive patients. Blood Press. 1992;1:92–101[Medline]
  40. Hakamaki T, Lehtonen A. Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Int J Clin Pharmacol Ther. 1997;35:227–230[Web of Science][Medline]
  41. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens. 2000;14:175–180[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi
Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients
Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?